The transformation of glucose into glycogen occurs by chemical reactions carried out by specific enzymes ([@b5-gmb-36-502]), and a deficiency in one of these leads to the accumulation of glycogen, resulting in hereditary disorders known as glycogen storage diseases (GSD) or glycogenosis ([@b25-gmb-36-502]). There are currently 12 types of GSD, presenting differences in age of onset of symptoms, affected organs, specific enzyme defect, and clinical severity, and each GSD is named after specific enzyme defect and organ impairment ([@b10-gmb-36-502]).

Deficiency in glucose-6-phosphatase (G6Pase, EC 3.1.3.9) activity causes GSD type I (GSD1), which is responsible for more than 90% of the cases, affecting mainly the liver and the kidneys. In addition to being a key enzyme in the regulation of blood glucose homeostasis, catalyzing the final steps of glycogenolysis and gluconeogenesis ([@b4-gmb-36-502]), it is also associated with the endoplasmic reticulum (ER) and functions as a multicomponent system ([@b28-gmb-36-502]).

The catalytic subunit of the system is located inside the ER and its defect causes subtype Ia (GSD Ia; OMIM 232200) ([@b13-gmb-36-502]). Additionally, there are transporters for the entry of substrate glucose-6-phosphate (G6P) into the ER and for the exit of the products, phosphate and glucose. Defects in these transporters cause subtype Ib (GSD Ib, OMIM 232220) ([@b8-gmb-36-502]). The mechanism of ER membrane glucose transport remains unknown ([@b7-gmb-36-502]).

The disease follows autosomal recessive inheritance and has an incidence of 1/100,000 to 1/400,000 live births, with up to 80% of the cases represented by subtype Ia ([@b2-gmb-36-502]; [@b10-gmb-36-502]). Patients with GSD Ia and Ib manifest a nearly identical metabolic phenotype, including hypoglycemia, hepatomegaly, hyperuricemia, lactic acidemia and hyperlipidemia ([@b19-gmb-36-502]), but GSD Ib patients also present neutropenia and myeloid dysfunction, and these individuals are susceptible to recurrent bacterial infections, aphthous stomatitis, and inflammatory bowel disease ([@b29-gmb-36-502]). Nonetheless, neutropenia is not manifested by all GSD Ib patients ([@b11-gmb-36-502]; [@b18-gmb-36-502]). It is seen in only 20% of cases ([@b9-gmb-36-502]), and it has been proposed that it could be due to *SLC37A4* mutations with residual transport activity ([@b11-gmb-36-502]). Clinical differentiation between GSD types 1a, 1b and 3 may not always be possible ([@b27-gmb-36-502]).

A biochemical essay for GSDI is useful to confirm the diagnosis and to recommend treatment; routine tests, however, do not allow the determination of the disease subtype ([@b6-gmb-36-502]). Furthermore, since the enzyme is not expressed in tissues such as fibroblasts or lymphocytes, their measurement is only possible by liver biopsy ([@b1-gmb-36-502]), an invasive procedure considered stressful by many families. cDNA cloning of *G6PC* and *SLC37A4* allowed the screening of mutations responsible for subtypes Ia and Ib, which enabled establishing an alternative, less invasive diagnosis based on molecular biology techniques using blood samples ([@b20-gmb-36-502]). A diagnostic flowchart for this procedure was created based on mutation analysis combined with clinical and biochemical abnormalities ([@b23-gmb-36-502]).

In the present study, we aimed to identify mutations in *G6PC* and *SLC37A4* genes in patients clinically suspected of having GSD Ia and Ib, and to compare the molecular findings with clinical diagnosis in these individuals and classify their disease types and subtypes.

Twelve unrelated subjects with clinical features suggestive of GSD Ia or Ib were studied. Inclusion criteria were based on typical clinical and laboratory findings, consisting of recurrent episodes of hypoglycemia associated with hepatomegaly, "doll face", and biochemical changes including hypoglycemia, hypertriglyceridemia, hypercholesterolemia, and hyperuricemia, with or without neutropenia. Patients were of diverse ethnicities, including Iberian, Italian, Afro-Brazilian, and Amerindian background. An Ashkenazi origin was not referred. This study was approved by the Institutional Review Board, and all patients or their legal guardians gave informed consent before inclusion.

Genomic DNA was extracted from peripheral blood leukocytes by using the standard phenol/chloroform method. Exons of the *G6PC* (five exons and 357 amino acids) and *SLC37A4* (eleven exons and 450 aminoacids) genes and their flanking intron/exon junctions were amplified by polymerase chain reaction (PCR) using previously described primers ([@b13-gmb-36-502]; [@b17-gmb-36-502]).

The PCR fragments were directly sequenced using a MegaBACE1000^®^ DYEnamic ET(Amersham Biosciences) apparatus. Sequencing was performed on both strands, and the analysis was done twice for each fragment, aiming to incresase confidence of the result. The obtained sequences were compared with the sequences of the *G6PC* (ENST00000253801) and *SLC37A4* (ENST0000330775) always available in the Ensembl genome browser.

The present study confirmed the diagnosis of GSD Ia in three patients, and of GSD Ib in two others.

Four known changes were detected in *G6PC,* consisting of one missense, one nonsense and two neutral mutations: c.432G \> A (rs161628) and c.1176T \> C (rs2229611). Three individuals presented the p.R83C (c.326C \> T) mutation (located in exon 2), two of them being homozygous and the other one compound heterozygous. A neutral mutation in exon five was found in the remaining allele of this last patient (p.Q347X; c.1118C \> T).

Concerning the *SLC37A4* gene, four changes were found, corresponding to a known missense mutation, a novel insertion (frameshift) and two neutral mutations: c.1287G \> A (rs8192696) and c.1076-28C \> T (rs201063857). The p.G149E (c.654G \> A) mutation in exon four was found in one homozygous patient. In another homozygous individual, the insertion of a T base between nucleotides 1338 and 1339 was detected in exon eleven. This change results in a reading frame modification and creates a premature stop codon ([Figure 1](#f1-gmb-36-502){ref-type="fig"}).

In addition to these mutations, some SNPs were also identified in this sample. In the remaining seven individuals, no disease causative mutation was found. Clinical and molecular data are summarized in [Table 1](#t1-gmb-36-502){ref-type="table"}.

The above results show that GSD1a was more prevalent than GSDIb in our case series. Considering the *G6PC* gene, p.R83C alters the amino acid that contributes to the active center of the enzyme. It is considered one of the most frequent mutations, seen both worldwide ([@b15-gmb-36-502],[@b16-gmb-36-502]; [@b21-gmb-36-502], [@b20-gmb-36-502]; [@b26-gmb-36-502]; [@b23-gmb-36-502]) and in Brazil ([@b24-gmb-36-502]). The present results corroborate these findings identify this as the most prevalent one among the mutant alleles. This being the case, the evaluation of this mutation by RFLP may allow the disease diagnosis without the need for automated sequencing, reducing cost and time of examination, since the restriction site mutation alters the enzyme *Hga*I cleavage pattern.

The remaining change (p.Q347X), already described in the literature, leads to truncation of the carboxy-terminal 11 amino acid residues in human G6Pase and inactivates its activity ([@b14-gmb-36-502]). It is also frequently observed in individuals with impaired G6Pase, being common among Caucasian patients in the United States ([@b15-gmb-36-502]) and Europe (north and south), representing 70% of all mutant alleles in these regions ([@b3-gmb-36-502]; [@b22-gmb-36-502]). Nevertheless, in the present sample, it was detected only in one allele of one patient, this being compound heterozygous for p.R83C.

In the *SLC37A4* gene, a missense mutation p.G149E and an insertion c.1338_1339insT were found, each one in an individual, both homozygous. In addition to these, SNP c.1076-28C \> T (rs201063857) was recently reported and shown to be present at a low frequency of heterozygosity (0.004%) in 570 participants of European descent ([@b30-gmb-36-502]). Our sample showed a high frequency, probably representing difference in ethnic background.

The amino acid glycine at position 149 is located in the transmembrane domain of the enzyme glucose 6-phosphate translocase, and the substitution of glycine to glutamic acid (p.G149E) changes the conformation of this enzyme. It is a rare change that has been reported only once in a Chinese family ([@b12-gmb-36-502]).

Finally, the present study allowed the identification of a new mutation, c.1338_1339insT, in individual 8. This patient is the fourth child of a consanguineous couple (first cousins) of Italian origin, whose third child died at the age of seven months with similar clinical symptoms. Pregnancy was complicated by maternal hypertension, and delivery was at 38 weeks of gestational age, weighting 3,590 g and measuring 51 cm. The child had hyperbilirubinemia after 48 h requiring exchange transfusion, and was released at the 5^th^ day after birth. At 10 days, a single convulsion was documented and at the age of three months hepatomegaly was denoted. During investigation, glycemia after fasting was 2 mg, total cholesterol was 251 mg%, and triglyceride 814 mg% (both with a reference value: \< 200), alkaline phosphatase was 477 IU/L (reference value: \< 400), and CK 144 IU/L (reference value: \< 190). Liver biopsy was performed for a histological study, which was compatible with GSD. After starting treatment with frequent meals, cornstarch, and dietary restriction of lipids and sugars (fructose, lactose, galactose, and sucrose), he presented normal neuromotor and somatic development, reaching a final height of 189 cm. Nevertheless, biochemical follow-up revealed variable degrees of hypercholesterolemia and hypertriglyceridemia, and he also developed hyperuricemia at the age of nine years, which was treated with 200 mg allopurinol twice a day. Renal function was always normal and neutropenia was never seen during routine exams, but at the age of 23 he presented an acute episode of sepsis and died after two days in another hospital with no further information available.

Although functional studies could not be performed to confirm that this mutation causes the disease, some aspects support the hypothesis. First, the insertion of the T base changed the reading frame, resulting in a different amino acid sequence and a premature stop codon. Second, no other causative mutation was found in this individual. Finally, the presence of parental consanguinity is compatible with the finding of this mutation in homozygosity.

In seven patients with clinical symptoms suggestive of GSDla and GSDIb no mutation was found in coding regions (exons) or adjacent introns. Mutations in other parts of the gene, including introns, were not studied, but it seems unlikely that they may cause an abnormal phenotype in these individuals. An alternative explanation to the negative results in this molecular study is the possibility of a misdiagnosis, since even with a careful evaluation based on laboratory and clinical findings, overlap with other types of GSD is possible. Thus further molecular studies would be indicated.

The molecular analysis of the two genes enabled diagnosis confirmation of GSDIa and Ib in four patients, without the need for liver biopsy. In addition, the identification of the mutation provided an additional tool for genetic counseling. Despite the limited number of subjects, our results showing that p.R83C was the most frequent mutation in *G6PC* in the present sample is compatible with international ([@b15-gmb-36-502],[@b16-gmb-36-502]; [@b21-gmb-36-502], [@b20-gmb-36-502]; [@b26-gmb-36-502]; [@b23-gmb-36-502]) and previous Brazilian studies ([@b24-gmb-36-502]). Thus, in every patient with GSD Ia or Ib, we propose to start with an investigation of this mutation and then to sequence the *G6PC* gene. For patients without identifiable genetic mutations, enzymatic essay or a further molecular study of other GSD genes remain diagnostic tools. Finally, in this study a new mutation was found and described.
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###### 

Clinical and molecular findings in *G6PC* and *SLC37A4* genes in the present sample.

  PN   G   Clinical diagnosis   PC                                           *G6PC*           *SLC37A4*                                                                                             
  ---- --- -------------------- -------------------------------------------- ---------------- ----------- ----- ----------------------------------------------------------------------------- ----- -----
  1    F   Ia                   [−](#tfn2-gmb-36-502){ref-type="table-fn"}   N/N              C/C         G/G   N/N                                                                           G/G   C/T
  2    M   Ia                   [+](#tfn3-gmb-36-502){ref-type="table-fn"}   p.R83C/p.R83C    T/C         G/G   N/N                                                                           G/G   C/T
  3    F   Ib                   [−](#tfn2-gmb-36-502){ref-type="table-fn"}   N/N              T/C         G/G   N/N                                                                           G/G   C/T
  4    M   Ib                   [+](#tfn3-gmb-36-502){ref-type="table-fn"}   N/N              C/C         G/G   N/N                                                                           G/G   C/T
  5    M   Ia or Ib ?           [−](#tfn2-gmb-36-502){ref-type="table-fn"}   N/N              C/C         G/G   p.G149E/p.G149E                                                               G/G   C/T
  6    F   Ia                   [−](#tfn2-gmb-36-502){ref-type="table-fn"}   p.R83C/p.R83C    C/C         G/G   N/N                                                                           G/G   C/T
  7    F   Ia                   [−](#tfn2-gmb-36-502){ref-type="table-fn"}   p.R83C/p.Q347X   C/C         G/G   N/N                                                                           G/G   C/T
  8    M   Ia                   [+](#tfn3-gmb-36-502){ref-type="table-fn"}   N/N              C/C         G/G   [\*](#tfn4-gmb-36-502){ref-type="table-fn"} c.1338_1339insT/c.1338_1339insT   G/G   C/T
  9    M   Ia                   [−](#tfn2-gmb-36-502){ref-type="table-fn"}   N/N              C/C         G/G   N/N                                                                           G/G   C/T
  10   M   Ia or Ib ?           [−](#tfn2-gmb-36-502){ref-type="table-fn"}   N/N              C/C         G/G   N/N                                                                           G/G   C/T
  11   M   Ia or Ib ?           [−](#tfn2-gmb-36-502){ref-type="table-fn"}   N/N              T/C         G/G   N/N                                                                           G/A   C/T
  12   M   Ia                   [−](#tfn2-gmb-36-502){ref-type="table-fn"}   N/N              T/C         G/G   N/N                                                                           G/G   C/T

Legend: PN = patient number; G = gender; PC = paretal consaguinity; F = female; M = male; N = normal;

− = negative;

\+ = positive.

Novel alteration.
